tirzepatide cardiovascular outcomes trial 2024 American Heart Association Scientific Sessions has started off with a bang! Results are in for the SUMMIT study: Treatment with (Mounjaro/ Zepbound) was associated with 38% ⬇️ in combined risk Evidence that tirzepatide protects against

The peptide economy is booming

Men on 10 mg lose significantly more than those who stay at 5 mg

Therefore, therapeutic principles acting via different receptors and postreceptor pathways seem attractive in view of potentially additive or synergistic effects

Five patients were on dialysis and one had stage 5 chronic kidney disease

After this initial month, it is recommended to increase the dose to 7 mg of Rybelsus once daily3

The longer the gap in treatment, the bigger the jump in risk up to a 22% increase for heart attack, stroke and death after two years off GLP-1s, largely erasing the cardiovascular benefits gained during treatment